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Abstract 
Growth differentiation factor 11 (GDF11) has been characterized as a key 
regulator of differentiation in cells that retain stemness features, despite some 
controversies in age-related studies. GDF11 has been poorly investigated in 
cancer, particularly in those with stemness capacity, such as hepatocellular 
carcinoma (HCC), one of the most aggressive cancers worldwide. Here, we 
focused on investigating the effects of GDF11 in liver cancer cells. GDF11 
treatment significantly reduced proliferation, colony and spheroid formation in 
HCC cell lines. Consistently, down-regulation of CDK6, cyclin D1, cyclin A, and 
concomitant upregulation of p27 was observed after 24 h of treatment. 
Interestingly, cell viability was unchanged, but cell functionality was 
compromised. These effects were potentially induced by the expression of E-
cadherin and Occludin, as well as Snail and N-cadherin repression, in a time-
dependent manner. Furthermore, GDF11 treatment for 72 h induced that cells 
were incapable of sustaining colony and sphere capacity in the absent of 
GDF11, up to 5 days, indicating that the effect of GDF11 on self-renewal 
capacity is not transient. Finally, in vivo invasion studies revealed a significant 
decrease in cell migration of hepatocellular carcinoma cells treated with GDF11 
associated to a decreased proliferation judged by Ki67 staining. Data show that 
exogenous GDF11 displays tumor suppressor properties in HCC cells.  
 
Keywords: GDF11; Huh7 cells; HCC; Cell cycle; Liver cancer; Hep3B cells 
 
 
 
Ac
c
pte
d m
an
us
rip
t
3 
 
1. Introduction 
Liver diseases represent one of the main challenges in public health. 
Changes in human habits tend to increase the prevalence of severe liver 
diseases, such as steatohepatitis, cirrhosis, viral hepatitis and liver cancer [1]. 
Hepatocellular carcinoma (HCC) is one of the most prevalent and aggressive 
tumor worldwide with high rate of postsurgical recurrence [2-4], and despite the 
outstanding progress made in the last decade in identifying new therapeutic 
approaches to target canonical proliferation and survival pathways, the potential 
use of non-canonical molecules and the molecular basis of their anti-
proliferating activity are currently being studied directed to provide new 
therapeutic targets [5]. 
Growth differentiation factor 11 (GDF11) is a member of the subfamily of the 
bone morphogenic proteins, and of the superfamily of the transforming growth 
factor beta (TGF-b). GDF11 is critical for organogenesis and development, 
particularly for skeletal system. Knock-out for mouse Gdf11, or for the furin-like 
convertase (Pcsk5), which activates GDF11 to a mature form, results in skeletal 
development defects and lethality in uterus [6, 7].  
Recently, some controversies have emerged about the effects of GDF11 in 
rejuvenation process [8]. While some groups report that GDF11 expression 
reduces with age, and its restoration induces proliferation and differentiation of 
progenitor cells (satellite cells) in the skeletal [9] and cardiac muscle [10], 
reversing the age-related hypertrophy, others state that GDF11 significantly 
inhibits muscle regeneration and decreases satellite cell expansion in mice [11, 
12]. This debating question is also associated with the great similarity of GDF11 
with myostatin (or GDF8) and the poor specificity of some commercial 
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antibodies [13]. Aside of these controversial functions of GDF11 in age-related 
disorders, both outlooks have in common that cells, with some stemness 
properties, are targeted by the GDF11, notably in development process [14-16].  
Given that cancer cells, with stemness features, are recognized as key 
therapeutic target, due to their capacity of sustained proliferation and migration, 
possibly driving tumor progression and resistance to treatment, we aimed at 
figure out the effects of GDF11 in HCC-derived cell lines. Although some 
studies revealed that GDF11 expression correlates with poor prognosis in 
colorectal [17] and breast cancer [18], it has been poorly studied in this kind of 
disease. Recently, Bajikar and collaborators [19] reported that GDF11 exerts 
tumor suppressive functions in triple-negative breast cancer cells. Loss of 
function of GDF11 in breast cancer has been notably related to deficient 
maturation due to the convertase PCSK5, which activates bioactive GDF11 
from its immature form. The present study is the first one related to liver cancer 
and provides evidence that GDF11 could be a good candidate for new 
therapeutic options. 
 
2. Materials and Methods 
 
2.1 Cell culture 
Huh7, Hep3B, Hepa1-6, HepG2, SNU-182 and MDA-MB-231 cell lines were 
obtained from the American Type Culture Collection (ATCC, Manassas, VA, 
USA). Cells were cultured in William’s medium supplemented with 10% fetal 
bovine serum (FBS, Hy-Clone, Logan, UT, USA), 100 U/ml ampicillin and 100 
µg/ml streptomycin (Thermo Fisher Scientific, Waltham, MA, USA). Cells were 
maintained at 37°C in a 5% CO2 and 90% humidity atmosphere. Cells were 
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plated in plastic culture bottles (Sigma-Aldrich, Saint Louis, MO, USA). All cell 
lines were mycoplasma free.  
2.2 Main experimental design 
Cells were exposed to 50 ng/ml GDF11 [20] for different times. GDF11 was 
added to culture media every 24 h and cells were recovered after 72 h for 
experiments, as depicted in supplementary figure 1A.  
In order to determine whether GDF11 effects are not transient, and remain after 
growth factor withdrawal, we performed additional experiments, in which cells 
were treated every 24 h up to 72 h, then harvested and re-plated without 
GDF11. Spheroid and colony formation were evaluated up to 5 days in the 
absent of GDF11 (Supplementary figure 1B).  
 
2.3 Western blotting 
Western blot was conducted as we previously reported [21]. PVDF 
membranes were probed with specific antibodies as described in the 
supplementary table 1. Horseradish peroxidase-conjugated antibodies were 
used according to the primary antibodies. Blots were exposed using Super 
Signal West Pico Chemiluminescent substrate (Pierce Biotechnology, USA).  
Signal was detected using Gel Logic 2500 (Kodak, Rochester, NY, USA). 
 
2.4 Immunofluorescence assays 
Immunofluorescence was conducted as previously reported [22], briefly, cells 
were treated for different times with GDF11, and then fixed with 4 % 
paraformaldehyde in phosphate-buffered saline (PBS). Samples were 
permeabilized with 0.01 % (v/v) Triton-X 100 for 30 min and blocked with 3 % 
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(w/v) bovine serum albumin (BSA) in PBS for 30 min and subsequently 
incubated with primary antibodies anti-occludin (Santa Cruz Biotechnology 
81812, dilution 1:100), anti-snail (Santa Cruz Biotechnology 28199, dilution 
1:100), anti-E-cadherin (Santa Cruz Biotechnology 21791, dilution 1:100) and 
anti-N-cadherin (Santa Cruz Biotechnology 59987, dilution 1:100). Nuclei were 
counterstained with 1 μg/mL 4′,6-diamidino-2-phenylindole (DAPI) (Sigma-
Aldrich). Images were obtained using a multi-photon confocal microscope (Carl 
Zeiss LSM-780 NLO, Oberkochen, Germany). 
2.5 Cell proliferation 
Cell proliferation was addressed by CCK-8 kit (Dojindo Lab, Kumamoto, 
Japan), following manufacturer´s instructions. 
 
2.6 Spheroid formation  
Cells were seeded in six-well low attachment plates, (Millipore-Sigma, Saint 
Louis MO, USA). The cultures were supplemented every 24 h with 50 ng/ml of 
GDF11 for five days. The spheroids were counted and photographed using an 
inverted microscope Carl Zeiss VERT.A1. 
 
2.7 Wound-healing assay 
Cells were seeded in six-well plates to approximately 90% of confluency. In 
each well a couple of wounds were created with a 20 μl pipette tip. Plates were 
washed three times with PBS to remove detached cells. Subsequently, media 
were added supplemented or not with FBS in presence or absent of GDF11.  
The healing response was monitored every 24 h up to 72 h when photography 
register was performed. 
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2.8 Cell functionality by MTT assay 
Cell functionality was addressed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) test, using the Vybrant MTT Cell 
Proliferation Assay Kit (Thermo Fisher Scientific), following 
manufacturer´s instructions.  
 
2.9 Clonogenic assay  
After 72 h under GDF11 treatment, 1x103 cells were seeded into 6-well plates in 
triplicate and maintained in GDF11-free media, in presence or absent of FBS. 
After 10 days, colonies were stained with crystal violet, photographed and 
counted. 
 
2.10 Invasion study using a chick embryo chorioallantoic membrane (CAM) 
assay 
Chick embryo CAM model was used to study invasion properties, following 
previous method reported by our group and others [23-25]. Briefly, ten fertile 
chick (Gallus domesticus) eggs (ALPES SA Farms, Puebla, Mexico) were 
randomly separated in two groups. Eggs were incubated at 37.8°C and 60% 
humidity up to 22 HH of embryo stage development. Then, shells were wiped 
with 70% ethanol, and  1 cm2 window was done. The vitelline membrane was 
dissected and 1x106 cells, treated or not with GDF11 for 72 h and labeled with 
vibrant CFDA SE cell tracer kit (Thermo Fisher Scientific), were introduced onto 
the CAM, in the convergence of two blood vessels, using 30 µl of Matrigel 
(Sigma-Aldrich) as substrate. The window in the shells was covered with sterile 
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adhesive tape and eggs were incubated as above for 2 and 4 days. CAM were 
recovered and immediately fixed with 4% paraformaldehyde in PBS. Paraffin 
sections (5 µm) were obtained for immunofluorescence using anti-beta-catenin 
antibody (Cell Signaling #9562). Proliferation was addressed by 
immunofluorescence using anti-Ki67 antibody (abcam 15580; dilution 1:100). 
Nuclei were counterstained with 1 μg/ml DAPI. Images were acquired using a 
multi-photon confocal microscope (Carl Zeiss LSM-780 NLO). 
 
2.11 Real-time quantitative reverse transcriptase-polymerase chain reaction 
(qRT-PCR) 
One μg total RNA was reverse transcribed in 20 μl reaction volume with a 
SuperScript (Invitrogen Corp.) first-strand synthesis kit according to the 
manufacturer’s instructions. Oligonucleotide primers were designed using 
Primer3 v.0.4.0 (http://frodo.wi.mit.edu/primer3/) as describe [26]. The qRT-
PCR analysis was performed with a CFX96 Touch (Bio-Rad) thermal cycler in a 
96-well reaction plate. The 10 μl PCR reaction mix contained 5 μl 2X SYBR 
Green PCR Master Mix (Bio-Rad), 200 nM of each primer, and 1 μl cDNA 
template. Reactions were incubated for 10 min at 95°C followed by 40 cycles of 
30 sec at 95°C and 60 sec at specific primer temperature. The expression level 
of ribosomal protein S18 (rs18) was used as reference. Relative gene 
expression levels were calculated using the formula 2 (-∆∆Ct). Primer sequences 
are listed in supplementary table 2. 
2.12 Protein quantification 
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The protein content was determined by using the bicinchoninic acid method 
(BCA, Pierce, Thermo Fisher Scientific.), following the manufacturer's 
instructions. 
 
2.13 Statistical analysis  
The results are presented as the average of at least three independent 
experiments. A One-way ANOVA followed by Tukey post-test was performed 
for the analysis of cell viability, mitochondrial functionality by MTT, number of 
spheroids and number of colonies in cell sensitization experiments whit GDF11. 
t-student test was performed for the analysis of the numbers of spheroids. 
 
3. Results 
3.1 HCC cells respond to GDF11 treatment by activating Smad3  
To figure out whether HCC-derived cells respond to GDF11, Huh7 and Hep3B 
cells were treated with 50 ng/ml GDF11 up to 60 min. Activation of the 
canonical signaling pathway was addressed by immunoblot of Smad3. Figure 
1A shows that Smad3 is rapidly activated by phosphorylation 5 min, in Huh7 cell 
line, and 30 min in Hep3B cell line, after GDF11 treatment. Activation remains 
up to 60 min. To explore impact in cell viability, Huh7 and Hep3B cells were 
treated at different times with GDF11. Time-course analysis up to 72 h of 
treatment demonstrates that GDF11 has no significant impact on cell viability 
(Figure 1B), while CdCl2 (5 µM, 6 h), used as a positive control, reduces cell 
viability. In addition, morphology inspection of cell culture at 72 h revealed small 
changes in cells, including a flat-like phenotype and a decrease in cell density in 
both cell lines (Figure 1C). 
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3.2 GDF11 impairs cell proliferation and cycle progression  
Next, we decided to address cell proliferation; although no significant effect was 
observed on cell viability, GDF11 was shown to decrease Huh7 cell proliferation 
starting after 48 h GDF11 treatment and being statistically significantly at 72 h in 
the absence or presence of FBS (Figure 2A), which was used as a competitor. 
In addition, a wound-healing assay revealed an impaired repair process at 72 h 
under GDF11 treatment compared with untreated cells (Figure 2B). The 
analysis of the content of key cell cycle proteins shows that positive regulators 
such as Cyclin A, Cyclin D1 and CDK6 decreases in a time dependent manner, 
while CDK inhibitor p27 increases (Figure 2C). Consistent with results observed 
in Huh7 cells, Hep3B cells under GDF11 treatment showed similar effects in cell 
proliferation (Figure 2D) and wound-healing assay (Figure 2F). Although 
viability was not affected in both HCC-derived cell lines, cell functionality, 
evaluated by MTT assay was significantly decreased starting after 24 h of 
treatment, in Huh7 cells, and 48 h in Hep3B cells, explaining the effects 
observed in proliferation and wound-healing (Figure 2G).  
 
3.3 GDF11 decreases spheroid formation capacity and the expression of genes 
related to aggressiveness 
Previous results strongly suggest that GDF11 exerts tumor suppressive effects. 
To gain more evidence, we performed studies of spheroid formation under 
GDF11 treatment every 24 h for 5 days. Cells treated with GDF11 exhibited 
fewer spheroids at day 5 (39%, in Huh7 cells; and 34% in Hep3B), as compared 
with untreated cells at the same time (Figure 3A). Even more, spheroids 
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observed under the GDF11 treatment were smaller (25% in Huh7 cells; and 
40% in Hep3B) than those formed in the absent of treatment. 
The analysis of the expression of some of the key well-characterized markers of 
cancer cell aggressiveness, revealed an increment of messenger RNA of 
CD133, CD24, CK19 and EpCAM particularly, the last one was significantly 
diminished only in Hep3B with no changes in Huh7 cells (Figure 3B). 
 
3.4 GDF11 promotes mesenchymal epithelial transition 
Next, we decided to address the expression of some mesenchymal and 
epithelial key markers in cells under GDF11 treatment. The immunoblot 
revealed a decrement of mesenchymal markers, such as Snail and N-cadherin, 
and the increment of epithelial markers, such as occludin and E-cadherin, in a 
time-dependent manner (Figure 4A and B), interestingly mesenchymal markers 
remain below levels of not treated cells, while epithelial markers decrement 
peaked at 24 h and then decreased to control values. To gain more confidence 
of these data, we analyzed the content of these proteins by 
immunofluorescence, figure 4C and D show the colocalization of Snail and E-
cadherin; and N-cadherin and Occludin, respectively, in both cases the 
expression of the mesenchymal proteins (Snail or N-cadherin) was considerably 
diminished, and the epithelial ones was increased, confirming the immunoblot 
experiments. Similar results were obtained in Hep3B exhibiting an increment in 
the expression of E-cadherin and occludin, and decrement in N-cadherin, in a 
time-dependent manner (Supplementary figure 2) 
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3.5 The effects elicited by GDF11 for 72 h of treatment remain in the absence of 
the factor.  
To figure out whether the effects displayed by GDF11 induce a long-lasting or a 
transient cellular reprograming, cells were treated with GDF11 every 24 h for 
three days then, cells were harvested and processed to explore the capacity of 
colony and spheroid formation for five days, in presence or absence of serum 
as competitor. Figure 5A shown that Huh7 cells treated with GDF11 remarkably 
decreased the ability to form colonies, in the presence or absence of FBS. 
Similarly, spheroid formation was significantly diminished in both cell lines 
(Figure 5 B and C), interestingly a better effect was observed in Huh7 cell line 
practically abrogating the spheroid formation capacity. Serum supplementation 
in the media did not rescue cells from the static phenotype (Supplementary 
figure 3), but the number of spheroids were different in the presence or absent 
of FBS in NT cells. Reprogramming experiments showed that cells exposed to 
GDF11 were unable of sustaining their colony and sphere forming capacity, 
indicating that the effect of GDF11 on self-renewal capacity is not transient. 
 
3.6 GDF11 impairs invasion capacity  
To address one of the key hallmarks of malignancy, we assayed invasion 
property in cells treated or not with GDF11. 1x106 cells were grafted in the CAM 
of the chick embryo (Figure 6A). Figure 6C shows the complete control CAM 
with no cells, in order to observe normal morphology of the CAM. Cells were 
grafted in the area labeled with the yellow circle; the eggshell was covered with 
sterile tape. After two or four days of incubation at 37 °C, the CAM was 
recovered fixed and paraffin embedded for immunofluorescence and confocal 
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microscopy. We started exploring the effect at day four; at this time we 
observed embryo lethality only with not treated cells (Figure 6B). Microscopy 
inspection revealed few disaggregated not treated cells remaining in the grafted 
zone (Supplementary figure 4A, white arrows), and some cells were observed in 
the distal zone of the CAM (green cells), indicating an ongoing invasion process 
(Supplementary figure 4C). The same experimental setting with GDF11 treated 
cells revealed some significant compacted aggregates of cells (Supplementary 
figure 4B, yellow arrow heads), and some of them in transit (Supplementary 
figure 4B, white arrows). No cell was detected in the distal CAM 
(Supplementary figure 4D). Remarkably, chick embryos in the eggs inoculated 
with GDF11 treated cells were still alive (Figure 6B).  
In order to analyze the invasion process at an early time point, we decided to 
incubate the eggs only for two days. Microscopic analysis of the complete CAM 
revealed that most of the untreated cells were gone (Figure 6D). In fact, some 
of chick embryo dies also at this time, however, cells treated for three days with 
GDF11 remained covered by the CAM and cell localization suggests an attempt 
of migration, but most of the cells still there (Figure 6E). The CAM zones near to 
the cell cumulous strongly express beta catenin (yellow arrow, and figure inset), 
probably as a response to Huh7 cells reprograming induced by GDF11; in 
comparison, beta catenin expression in CAM with non-treated cells, was weak, 
suggesting degradation. In order to address the cell proliferation status in the 
invasion experiment, we proceeded to detect Ki67 protein content by 
immunofluorescence; figure 6F shows more proliferating cells in CAM grafted 
with not treated Huh7 cells comparing with those under GDF11 treatment; 
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remarkably, Ki67 positive cells were more abundant in the lower zone of the 
CAM, indicating more proliferative capacity (yellow arrow; Figure 6F).  
To corroborate the GDF11-induced invasion restriction, we performed the CAM 
experiment using Hep3B cells. The results depicted in supplementary figure 3E 
show disaggregated not treated cells in the engraftment zone, cells seems to be 
disabled to form cell to cell interactions, in comparison with GDF11 treated cells 
that exhibited a well compacted cell cumulous with well defined cell interactions, 
the vascular zone exhibited not treated cells in blood vessels, effect that was 
absent in GDF11-treated cells, interestingly, the tumor was well delimited (white 
arrows, supplementary figure 4), suggesting that treated cells were enable to 
degrade the basal membrane, as observed in an in situ tumor. The distal zone 
in the experiment with not treated cells shows many disaggregated cells in the 
CAM, in comparison of the GDF11 experiment with few cells; remarkably, the 
size of this zone was thicker than that with not treated cells. Thus, these data 
strongly suggest that GDF11 significantly reduces invasive property. 
 
3.7 GDF11 decreases spheroid formation in other cancer cell lines.  
Finally, to corroborate that the tumor suppressive effects displayed by GDF11 
are not restricted to Huh7 and Hep3B cell line, we treated for three days the 
human hepatoma cell line HepG2 (Figure 7A), the mouse HCC cell line Hepa1-
6 (Figure 7B), the human breast cancer cell line MDA-231 (Figure 7C), and the 
human HCC cell line SNU-182. In all cases, GDF11 significantly decreases 
spheroid-forming capacity, suggesting a conserved effect among cancer cells 
with some stemness phenotype.  
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4. Discussion 
 
HCC accounts for 90% of primary liver cancer, with increasing new cases every 
year, raising a warning worldwide [4, 27]. Although, some therapeutic options 
are currently well established, such as sorafenib administration for advanced 
tumors, local ablation or resection, these options only provide some limited 
benefits in terms of patient survival. Besides, liver transplantation remains a 
great challenge due to the limited number of donors.  
Investigation of signaling pathways involved in the control of proliferation, 
survival or the metabolism of cancer cells is crucial to define novel alternative 
therapeutic approaches.  
GDF11, a relatively new member of the TGF-b superfamily, has been showed 
to display biological effects in a wide range of cell types. It is particularly 
interesting that most of the cells that respond to GDF11 exhibit some degree of 
stemness phenotype [9, 20]. Along this characteristic, we hypothesized that this 
growth factor could exert some effects in HCC-derived cell lines, particularly in 
those retaining stemness features. It was reported that Huh7 cell line expresses 
some of the key stemness markers, such as Nanog, Oct4 or Sox2. It has been 
also reported that increased expression of these genes in Huh7 cells is related 
to the increment of stemness [28, 29], particularly when cells are forming 
spheroids [30]. The first evidence that Huh7 and Hep3B cells respond to 
GDF11 was the activation of one of the canonical signal transducers, 
specifically the phosphorylation of Smad3 [11, 20], which was strongly detected 
after 5 min of GDF11 treatment in the case of Huh7 and, at 30 min in Hep3B 
cells, and remained activated along 60 min (Figure 1A). It is well-characterized 
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that some members of the TGF-b display effects in epithelial cells that modulate 
survival or proliferation [31]. Interestingly, we found that viability is unaffected up 
to 72 h under GDF11 treatment (Figure 1B), with no outward changes in cell 
phenotype. However, cell proliferation is clearly diminished at 72 h, in presence 
or not, of the proliferative action of FBS (Figure 2A and D), suggesting cytostatic 
effects similar to those observed with other members of the TGF-b family. 
Indeed, it is reported that TGF-b by itself, displays cytostatic and apoptotic 
functions that restrain cell growth, avoiding the hyperproliferative disorders, 
even in Huh7 and Hep3B cells [32, 33]. This novel effect, elicited by GDF11 in 
liver cancer cells, confirms the well-conserved cytostatic effect in the TGF-b 
family, as exemplified by the analysis of the content of the main cell cycle 
regulating proteins; cyclins A and D1, and cdk6 were downregulated, and p27 
was overexpressed, these effects being particularly evident at 72 h (Figure 2C). 
Similarly, GDF11 significantly attenuated the proliferation of the neural stem cell 
line Cor-1, downregulating key positive cell cycle proteins [20]. In addition, this 
work by Williams and collaborators showed that cell migration is impaired by 
GDF11 as we also observed (Figure 2B and F).  
Based in the fact that stemness feature is increasing in spheroid or 3D culture, 
particularly in cells used in this study [29, 30], we observed that the number and 
the size of spheroids decreased in the presence of GDF11 at 72 h of repeated 
treatment (50 ng/ml, every 24 h) in both HCC cell lines. We found similar effects 
in HepG2 (Figure 7A), a human hepatoma cell line capable to form spheroids as 
well [30], and in SNU-182, another human HCC cell line from a high aggressive 
tumor. Interestingly, when comparing the human liver cancer cell lines, GDF11 
displayed greater effects in Huh7 and Hep3B than in HepG2, although, in the 
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last one, decrement in sphere formation was statistically significant, confirming 
the preference of GDF11 on cells with stemness feature. Similar results were 
reported by Bajikar and collaborators in triple negative breast cancer cell lines 
[19], even more, Hepa1-6, MDA-MB-231 and SNU-182 cell lines presented 
similar effects with some differences in the number of spheroids, but in all cases 
with significant changes (Figure 7). 
To gain more evidence, we performed the analysis of the messenger RNA 
levels of key molecular markers for aggressive cancers and stemness (Figure 
3B), cytokeratin 19 (ck19) has been closely related to poor prognosis and high 
recurrence in HCC [34], the effect on ck19 expression, induced by GDF11, was 
the most relevant, in terms of absolute values comparing with NT cells, prom1 
(CD133) and epcam (EpCAM) also are well characterized stemness markers, 
being CD133 most significant in stages I, while the prognostic role of EpCAM is 
more effective in advanced stages [35], interestingly, the effect of GDF11 in 
epcam expression was different in the HCC cell lines studied here, Huh7 cells 
did not respond to the GDF11 treatment exhibiting no changes in the 
expression, however, Hep3B, which a more aggressive cell line, diminished the 
expression since 6 h of treatment, supporting the findings by Chang and 
coworkers [35]. These results strongly suggest that GDF11 antitumorigenic 
properties are more relevant in advanced tumors. Finally, cd24 is another well-
known marker for stemness and aggressive HCC [36], our data clearly show a 
decrement since 6 h in Huh7 and at 12 h in Hep3B, once again the difference in 
stemness capacity is evident in both cell lines, but in both cases GDF11 
displays antitumorigenic effects. 
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The analysis of mesenchymal and epithelial markers revealed a clear GDF11-
induced mesenchymal to epithelial transition phenotype. A time-dependent 
decrement in the expression of mesenchymal-related proteins such as Snail 
and N-cadherin, and increased of epithelial markers, such as E-cadherin and 
Occludin (Figure 4) [37], was confirmed by Western blot and 
immunofluorescence. The gain of an epithelial phenotype was simultaneously 
associated to a significant decrease in colony and spheroid formation capacity 
(Figure 5), and to a decreased capacity in invasion (Figure 6), as addressed by 
the CAM assay. Interestingly, in the CAM assay we observed a degradation of 
the basal membrane, a key condition for invasion in the experiment using not 
treated cells, and in the case of the experiment with GDF11 treated cells the 
membrane was preserved suggesting a distinctive phenotype of an in situ 
tumor, in addition treated cells were presented forming cumulous, probably 
because the increment of E-cadherin expression (Figure 4 and supplementary 
figure 2). 
All these data clearly show that GDF11 induces an anti-tumor response in HCC 
cells, directed to decreases aggressiveness by attempting reverse the 
mesenchymal to epithelial phenotype. 
The decrement of the invasive phenotype was also found in triple negative 
breast cancer cell lines [19]. The effect was associated to an increase in the 
expression of E-cadherin, supporting our findings in HCC-derived cells. 
Importantly, we reported that GDF11 effects were not transient, and may evoke 
a cellular reprograming in HCC cells. Indeed, treatment for 72 h with GDF11 
sustained the effects even five days in culture in the absent of GDF11. 
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Although, a low frequency of mutations in GDF11 and a significant enrichment 
in the convertase PCSK5 locus have been reported in breast cancer [19], we 
did not find significant presence of mutations in those genes in HCC according 
to The Cancer Genome Atlas (TCGA, data not shown). However, in human 
HCC the expression level of GDF11 observed no changes, but in 
cholangiocellular carcinoma (CCC), significant differences were found 
increasing 1.55-fold change in tumors versus normal tissue (Supplementary 
figure 5), (36 patients for CCC and 371 for HCC; https://portal.gdc.cancer.gov 
and http://firebrowse.org), in the case of PCSK5 gene expression the TCGA 
reports significant changes in both HCC and CCC (1.56-fold and 2.31-fold 
change versus normal tissue. 
These data suggest that changes in basal expression in GDF11 and PCSK5 
genes, are rare events in HCC and probably not responsible to the loss of 
function of GDF11, maybe some epigenetic silencing mechanism could be 
related to loss of function of GDF11. Nevertheless, we clearly demonstrated 
that recombinant human GDF11 induces an antitumorigenic effect with no 
relevance in cell death, but lessening aggressiveness by promoting a cytostatic 
phenotype and repressing invasion. 
In conclusion, we are reporting tumor suppressive properties of GDF11 in HCC-
derived cells restricting self-renewal capacity, setting GDF11 as a good 
candidate for therapy and biomarker in liver cancer.    
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Figure legends 
Figure 1. HCC cells respond to GDF11 treatment activating Smad3 with no 
effects on cell viability. Huh7 and Hep3B cells were treated for different times 
with GDF11 (50 ng/ml). A) Western blot analysis of the Smad3 phosphorylation. 
Actin was used as loading control. B) Time-course analysis of cell viability 
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determined by crystal violet staining, cadmium chloride (Cl2Cd, 5µM for 6h) was 
used as positive control (PC). Each column represents the mean ± SEM of at 
least four independent experiments carried out by triplicate.  C) Cell morphology 
under GDF11 treatment at 72 h, cells were treated every 24 h with GDF11 up to 
72 h. Representative images of at least four independent experiments. Original 
magnification 200X. 
 
Figure 2. GDF11 impairs proliferation, migration and cellular function. A) 
Huh7 cell proliferation addressed by CCK-8 in the absent or the presence of 
fetal bovine serum (FBS). B) Wound-healing assay, Huh7 cells were treated 
every 24 h with GDF11 up to 72 h. Representative images of at least four 
independent experiments. C) Western blot of the main cell cycle proteins and 
densitometric analysis. D) Hep3B cell proliferation addressed by CCK-8 in the 
absent or the presence of FBS.  Each point represents the mean ± SEM of at 
least four independent experiments carried out by triplicate, F) Wound-healing 
assay, Hep3B cells were treated every 24 h with GDF11 up to 72 h. 
Representative images of at least four independent experiments. G) 
Mitochondrial functionality by MTT assay in HCC cell lines, each column 
represents the mean ± SEM of at least three independent experiments carried 
out by triplicate. Images are representative of at least three independent 
experiments. *, p ≤ 0.05 vs NT cells at 72 h. 
 
Figure 3. GDF11 decreases spheroid formation capacity and the 
expression of genes related to aggressiveness. A) Spheroid counting at 72 
h, Huh7 and Hep3B cells were treated every 24 h with GDF11 (50 ng/ml) up to 
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72 h, each point represents an independent experiment, we reported the 
median ± SEM of at least ten independent experiments. Images are 
representative of at least ten independent experiments, original magnification 
100X. &, p ≤ 0.05 vs NT cells at 72 h. B) Messenger RNA levels of key genes 
related to cancer aggressiveness, relative expression to not treated (NT) cells is 
demonstrated as means ± SEM. *, p ≤ 0.05 vs NT cells. 
 
Figure 4. GDF11 promotes mesenchymal to epithelial transition. A) Time-
course analysis by Western blot of representative epithelial (E-cadherin and 
occludin) and mesenchymal (Snail and N-cadherin) markers in Huh7 cells 
treated with GDF11 (50 ng/ml) and, B) corresponding densitometric analysis. 
Each column represents the mean ± SEM of at least three independent 
experiments carried out by triplicate. Images are representative of at least three 
independent experiments. *, p ≤ 0.05 vs NT cells. Immunofluorescence 
determined by confocal microscopy of C) Snail and E-cadherin content and, D) 
N-cadherin and Occludin content. Images are representative of at least three 
independent experiments. Original magnification 360X. 
 
Figure 5. The effects elicited by GDF11 remains in the absent of the 
growth factor. Cells were treated every 24 h with GDF11 (50 ng/ml) up to 72h, 
after that, cells were harvested and we proceeded to analyze: A) colony 
formation and, B) spheroid formation with deprivation of GDF11. Experiments 
were conducted in the presence or absence of fetal bovine serum (FBS). For 
the number of colonies each column represents the mean ± SEM of at least 
three independent experiments carried out by triplicate. Representative images 
Ac
c
pte
d m
an
u
rip
t
28 
 
of the six-well plates. For spheroid formation, each point represents an 
independent experiment; we reported the median ± SEM of at least nine 
independent experiments. *, p ≤ 0.05 vs NT cells in presence of FBS (+FBS); &, 
p ≤ 0.05 vs NT cells in the absence of FBS (-FBS). 
 
Figure 6. GDF11 impairs invasive capacity. The chick embryo chorioallantoic 
membrane (CAM) model was used to address the invasion capacity as 
specified in Material and Methods. 1x106 cells treated or not with GDF11 for 72 
h, were engrafted in the top of the CAM in 30 µl of Matrigel. A) Schematic 
representation of the model used in the study. B) Survival plot of the chicken 
embryo, n=6 in each treatment. C) Representative confocal image composition 
of the control complete CAM, the yellow circle indicates the place were cells 
were placed. D) Confocal microscopic inspection of the entire CAM that 
received not treated Huh7 cells. E) Confocal microscopic inspection of the 
entire CAM that received GDF11 treated Huh7 cells for 72 h. CAM is identified 
by immunofluorescence of beta catenin (membrane in green, yellow arrows), 
DAPI was used for nuclei identification, Huh7 cells were traced with Vybrant 
CFDA SE cell tracer kit (white arrows). F) Ki67 immunofluorescence, positive 
cells in green (Alexa flour 488), nuclei in red (propidium iodide).  V, blood 
vessel. Images are representative of at least 6 eggs per condition. 
 
Figure 7. GDF11 decreases spheroid formation property in other cancer 
cell lines. Cells were treated every 24h with GDF11 (50 ng/ml) up to 72 h and 
we proceeded to spheroid counting in A) HepG2, hepatoblastoma cell line B) 
Hepa1-6, mouse hepatocellular carcinoma cell line, C) MDA-MB-231, triple 
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negative breast cancer cell line, D) SNU-182, grade III/IV human hepatocellular 
carcinoma cell line.  Each point represents an independent experiment; we 
reported the median ± SEM of at least six independent experiments. *, p ≤ 0.05 
vs NT cells at 72 h. 
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